Vascularized Tissue Engineering Mouse Chamber Model Supports Thymopoiesis of Ectopic Thymus Tissue Grafts

2010 ◽  
Vol 16 (3) ◽  
pp. 543-551 ◽  
Author(s):  
Natalie Seach ◽  
Monika Mattesich ◽  
Keren Abberton ◽  
Ken Matsuda ◽  
Daniel J. Tilkorn ◽  
...  
2008 ◽  
Vol 48 (4) ◽  
pp. 974-985 ◽  
Author(s):  
Zerina Lokmic ◽  
James L. Thomas ◽  
Wayne A. Morrison ◽  
Erik W. Thompson ◽  
Geraldine M. Mitchell

2008 ◽  
Vol 168 (9) ◽  
pp. 1141-1145 ◽  
Author(s):  
K. Felgentreff ◽  
W. Schupp ◽  
J. E. Otten ◽  
K. D. Rückauer ◽  
M. Uhl ◽  
...  

Biomaterials ◽  
2012 ◽  
Vol 33 (15) ◽  
pp. 3868-3879 ◽  
Author(s):  
Daniel J. Tilkorn ◽  
E. Michele Davies ◽  
Effie Keramidaris ◽  
Aaron M. Dingle ◽  
Yi-Wen Gerrand ◽  
...  

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Maryna Bondarava ◽  
Chiara Cattaneo ◽  
Bin Ren ◽  
Wolfgang E. Thasler ◽  
Volkmar Jansson ◽  
...  

2021 ◽  
Vol 14 (5) ◽  
pp. e241074
Author(s):  
Sevasti Konstantinidou ◽  
Colin R Butler ◽  
Benjamin Hartley ◽  
Claire Frauenfelder

Subglottic haemangioma presents as progressive obstruction in the neonatal and infantile airway, with a soft lesion seen during endoscopy. Diagnosis is based on macroscopic findings, biopsy is not usually performed and propranolol is first-line treatment. In contrast, ectopic thymus is a rare differential diagnosis for subglottic mass made by histopathological examination after excision or autopsy. In this article, we present a case of an infant with a subglottic lesion with endoscopic features consistent with haemangioma. After initial clinical response to propranolol, the patient represented with progressive stridor no longer responding to therapy. Open excision of the lesion was performed, and histopathology revealed ectopic thymus tissue. In this case, ectopic thymus tissue mimicked the presentation of subglottic haemangioma, and confirmation bias persisted due to an apparent initial clinical response to treatment with propranolol. In cases of subglottic mass refractory to medical treatment, excision of the lesion should be considered.


Author(s):  
Chloé D. Devillard ◽  
Christophe A. Marquette

Since the emergence of regenerative medicine and tissue engineering more than half a century ago, one obstacle has persisted: the in vitro creation of large-scale vascular tissue (>1 cm3) to meet the clinical needs of viable tissue grafts but also for biological research applications. Considerable advancements in biofabrication have been made since Weinberg and Bell, in 1986, created the first blood vessel from collagen, endothelial cells, smooth muscle cells and fibroblasts. The synergistic combination of advances in fabrication methods, availability of cell source, biomaterials formulation and vascular tissue development, promises new strategies for the creation of autologous blood vessels, recapitulating biological functions, structural functions, but also the mechanical functions of a native blood vessel. In this review, the main technological advancements in bio-fabrication are discussed with a particular highlights on 3D bioprinting technologies. The choice of the main biomaterials and cell sources, the use of dynamic maturation systems such as bioreactors and the associated clinical trials will be detailed. The remaining challenges in this complex engineering field will finally be discussed.


Sign in / Sign up

Export Citation Format

Share Document